Infant Bacterial Therapeutics today announces that new patent protection is granted in Australia
January 10, 2022 16:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) today announces that the Australian Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of...
Infant Bacterial Therapeutics tillkännager idag att nya patent har godkänts i Brasilien samt i Hong Kong
December 27, 2021 16:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) meddelar idag att patentverken i Brasilien och Hong Kong har godkänt ett patent för Lactobacillus reuteri som omfattar IBP-9414. IBP-9414 är den...
Infant Bacterial Therapeutics today announces new patent protection approvals in Brazil and in Hong Kong
December 27, 2021 16:30 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB today announces that the Patent Offices of Brazil and Hong Kong have approved a patent of Lactobacillus reuteri covering IBP-9414. IBT is currently developing its drug...
Infant Bacterial Therapeutics CFO lämnar bolaget
December 10, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics ABs Chief Financial Officer (CFO) Marie Louise Alamaa har idag lämnat IBT för att anta nya utmaningar. IBTs Controller, Michael Owens, har samtidigt tillträtt som ny...
Infant Bacterial Therapeutics CFO leaves the company
December 10, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics ABs CFO Marie Louise Alamaa left the company to pursue new opportunities. IBT’s Controller, Michael Owens, has assumed the responsibility of CFO moving forward. “I would...
EN BLINDAD UTVÄRDERING AV IBT:S CONNECTION STUDY – “SUSTAINED FEEDING TOLERANCE” (SFT) KORRELERAR MED KLINISKA UTFALL
December 06, 2021 13:47 ET
|
Infant Bacterial Therapeutics AB
En blind utvärdering av IBTs Connection Study kommer att presenteras av Professor Josef Neu, University of Florida, vid 2021 Hot Topics in Neonatology® den 6 december 2021. Utvärderingen avslöjar att...
A Blinded Evaluation of the Connection Study – Sustained Feeding Tolerance (SFT) Correlates to Clinical Outcomes
December 06, 2021 13:47 ET
|
Infant Bacterial Therapeutics AB
A blinded evaluation of IBT’s Connection Study will be presented by Professor Josef Neu, University of Florida, at the 2021 Hot Topics in Neonatology® on December 6, 2021. The evaluation reveals that...
Valberedning utsedd inför årsstämman 2022 i Infant Bacterial Therapeutics (IBT).
October 29, 2021 10:15 ET
|
Infant Bacterial Therapeutics AB
Stockholm, 29 oktober 2021. Styrelsens ordförande i IBT har etablerat en valberedning inför årsstämman, som avses hållas den 4 maj 2022. Ledamöterna har utsetts av IBTs, i förhållande till röstetalet,...
Nomination Committee appointed for the 2022 Annual General Meeting (AGM) in Infant Bacterial Therapeutics (IBT).
October 29, 2021 10:15 ET
|
Infant Bacterial Therapeutics AB
Stockholm, October 29, 2021. The Chairman of IBT has established a Nomination Committee for the AGM, which is planned to be held on May 4, 2022. The Nomination Committee is composed, according to...
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021
October 29, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021 Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the...